Mostrar el registro sencillo del ítem

Artículo

dc.creatorGarcía Revilla, Juanes
dc.creatorBoza Serrano, Antonioes
dc.creatorJin, Yiyunes
dc.creatorVadukul, Devkee M.es
dc.creatorSoldán Hidalgo, Jesúses
dc.creatorCamprubí Ferrer, Lluíses
dc.creatorRuiz Laza, Rocíoes
dc.creatorVenero Recio, José Luises
dc.date.accessioned2023-06-20T10:03:49Z
dc.date.available2023-06-20T10:03:49Z
dc.date.issued2023
dc.identifier.citationGarcía Revilla, J., Boza Serrano, A., Jin, Y., Vadukul, D.M., Soldán Hidalgo, J., Camprubí Ferrer, L.,...,Venero Recio, J.L. (2023). Galectin-3 shapes toxic alpha-synuclein strains in Parkinson's disease.. Acta Neuropathologica, 146, 51-75. https://doi.org/10.1007/s00401-023-02585-x.
dc.identifier.issn0001-6322es
dc.identifier.issn1432-0533es
dc.identifier.urihttps://hdl.handle.net/11441/147349
dc.description.abstractParkinson’s Disease (PD) is a neurodegenerative and progressive disorder characterised by intracytoplasmic inclusions called Lewy bodies (LB) and degeneration of dopaminergic neurons in the substantia nigra (SN). Aggregated α-synuclein (αSYN) is known to be the main component of the LB. It has also been reported to interact with several proteins and organelles. Galectin-3 (GAL3) is known to have a detrimental function in neurodegenerative diseases. It is a galactose-binding protein without known catalytic activity and is expressed mainly by activated microglial cells in the central nervous system (CNS). GAL3 has been previously found in the outer layer of the LB in post-mortem brains. However, the role of GAL3 in PD is yet to be elucidated. In post-mortem samples, we identifed an association between GAL3 and LB in all the PD subjects studied. GAL3 was linked to less αSYN in the LB outer layer and other αSYN deposits, including pale bodies. GAL3 was also associated with disrupted lysosomes. In vitro studies demonstrate that exogenous recombinant Gal3 is internalised by neuronal cell lines and primary neurons where it interacts with endogenous αSyn fbrils. In addition, aggregation experiments show that Gal3 afects spatial propagation and the stability of pre-formed αSyn fbrils resulting in short, amorphous toxic strains. To further investigate these observations in vivo, we take advantage of WT and Gal3KO mice subjected to intranigral injection of adenovirus overexpressing human αSyn as a PD model. In line with our in vitro studies, under these conditions, genetic deletion of GAL3 leads to increased intracellular αSyn accumulation within dopaminergic neurons and remarkably preserved dopaminergic integrity and motor function. Overall, our data suggest a prominent role for GAL3 in the aggregation process of αSYN and LB formation, leading to the production of short species to the detriment of larger strains which triggers neuronal degeneration in a mouse model of PD.es
dc.description.sponsorshipThe Michael J. Fox Foundation for Parkinson's Research ID: 11902es
dc.description.sponsorshipMinisterio de Ciencia e Innovación de España/FEDER/UE/PID2021-124096OB-I00es
dc.description.sponsorshipJunta de Andalucía/FEDER/EU P18-RT-1372es
dc.description.sponsorshipFEDER I + D + i-USE US-1264806es
dc.description.sponsorshipUK Research and Innovation - Future Leaders Fellowship MR/S033947/1es
dc.description.sponsorshipAlzheimer’s Society, UK - Grant 51es
dc.description.sponsorshipAlzheimer’s Research. UK - ARUK-PG2019B-020es
dc.formatapplication/pdfes
dc.format.extent25 p.es
dc.language.isoenges
dc.publisherSpringeres
dc.relation.ispartofActa Neuropathologica, 146, 51-75.
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectParkinson’s disease (PD)es
dc.subjectGalectin-3 (GAL3)es
dc.subjectα-synuclein (αSYN)es
dc.subjectLewy body (LB)es
dc.titleGalectin-3 shapes toxic alpha-synuclein strains in Parkinson's disease.es
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Bioquímica y Biología Moleculares
dc.relation.projectIDPID2021-124096OB-I00es
dc.relation.projectIDP18-RT-1372es
dc.relation.projectIDFEDER I + D + i-USE US-1264806es
dc.relation.projectIDMR/S033947/1es
dc.relation.projectIDARUK-PG2019B-020es
dc.relation.publisherversionhttps://doi.org/10.1007/s00401-023-02585-xes
dc.identifier.doi10.1007/s00401-023-02585-xes
dc.journaltitleActa Neuropathologicaes
dc.publication.volumen146es
dc.publication.initialPage51es
dc.publication.endPage75es
dc.contributor.funderThe Michael J. Fox Foundation for Parkinson's Researches
dc.contributor.funderMinisterio de Ciencia e Innovación (MICIN). Españaes
dc.contributor.funderEuropean Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER)es
dc.contributor.funderJunta de Andalucíaes
dc.contributor.funderUniversidad de Sevillaes
dc.contributor.funderAgencia Estatal de Investigación. Españaes
dc.contributor.funderUK Research and Innovationes
dc.contributor.funderAlzheimer’s Society, UKes
dc.contributor.funderAlzheimer’s Research. UKes
dc.description.awardwinningPremio Anual Publicación Científica Destacada de la US. Facultad de Farmacia

FicherosTamañoFormatoVerDescripción
s00401-023-02585-x.pdf5.139MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución 4.0 Internacional